PT3649124T - ¿compostos de fluoropiperidina como antagonistas puros do recetor 5-ht6 - Google Patents

¿compostos de fluoropiperidina como antagonistas puros do recetor 5-ht6

Info

Publication number
PT3649124T
PT3649124T PT187738323T PT18773832T PT3649124T PT 3649124 T PT3649124 T PT 3649124T PT 187738323 T PT187738323 T PT 187738323T PT 18773832 T PT18773832 T PT 18773832T PT 3649124 T PT3649124 T PT 3649124T
Authority
PT
Portugal
Prior art keywords
pure
receptor antagonists
fluoropiperidine
compounds
fluoropiperidine compounds
Prior art date
Application number
PT187738323T
Other languages
English (en)
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of PT3649124T publication Critical patent/PT3649124T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT187738323T 2017-08-07 2018-08-06 ¿compostos de fluoropiperidina como antagonistas puros do recetor 5-ht6 PT3649124T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201741028024 2017-08-07

Publications (1)

Publication Number Publication Date
PT3649124T true PT3649124T (pt) 2021-06-01

Family

ID=63678636

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187738323T PT3649124T (pt) 2017-08-07 2018-08-06 ¿compostos de fluoropiperidina como antagonistas puros do recetor 5-ht6

Country Status (26)

Country Link
US (1) US10973831B2 (pt)
EP (1) EP3649124B1 (pt)
JP (1) JP6808088B2 (pt)
KR (1) KR102190332B1 (pt)
CN (1) CN111051302B (pt)
AU (1) AU2018313049B2 (pt)
BR (1) BR112020002227A2 (pt)
CA (1) CA3071084C (pt)
CY (1) CY1124174T1 (pt)
DK (1) DK3649124T3 (pt)
EA (1) EA202090397A1 (pt)
ES (1) ES2874628T3 (pt)
HR (1) HRP20210822T1 (pt)
HU (1) HUE055186T2 (pt)
IL (1) IL272287B (pt)
LT (1) LT3649124T (pt)
MA (1) MA50036B1 (pt)
MD (1) MD3649124T2 (pt)
MX (1) MX2020001311A (pt)
PL (1) PL3649124T3 (pt)
PT (1) PT3649124T (pt)
RS (1) RS61886B1 (pt)
SG (1) SG11202000833YA (pt)
SI (1) SI3649124T1 (pt)
WO (1) WO2019030641A1 (pt)
ZA (1) ZA202000758B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020286003A1 (en) * 2019-05-24 2021-12-02 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293653B2 (en) * 2002-11-08 2009-05-14 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
MA50036B1 (fr) 2021-06-30
CY1124174T1 (el) 2022-05-27
SG11202000833YA (en) 2020-02-27
MD3649124T2 (ro) 2021-07-31
SI3649124T1 (sl) 2021-09-30
MX2020001311A (es) 2020-03-20
HRP20210822T1 (hr) 2021-08-20
US10973831B2 (en) 2021-04-13
CA3071084C (en) 2021-01-19
KR102190332B1 (ko) 2020-12-11
CN111051302B (zh) 2021-04-09
KR20200022517A (ko) 2020-03-03
EP3649124B1 (en) 2021-03-03
JP6808088B2 (ja) 2021-01-06
HUE055186T2 (hu) 2021-11-29
BR112020002227A2 (pt) 2020-07-28
IL272287A (en) 2020-03-31
ZA202000758B (en) 2021-03-31
RS61886B1 (sr) 2021-06-30
LT3649124T (lt) 2021-06-10
DK3649124T3 (da) 2021-05-31
JP2020526573A (ja) 2020-08-31
CA3071084A1 (en) 2019-02-14
EP3649124A1 (en) 2020-05-13
US20200155560A1 (en) 2020-05-21
AU2018313049A8 (en) 2020-02-27
MA50036A (fr) 2020-05-13
CN111051302A (zh) 2020-04-21
IL272287B (en) 2021-07-29
AU2018313049A1 (en) 2020-02-20
EA202090397A1 (ru) 2020-05-25
WO2019030641A1 (en) 2019-02-14
PL3649124T3 (pl) 2021-08-16
ES2874628T3 (es) 2021-11-05
AU2018313049B2 (en) 2020-07-09
NZ762057A (en) 2022-03-25

Similar Documents

Publication Publication Date Title
IL272056A (en) Heterocyclic compounds as adenosine antagonists
IL276400A (en) Dopamine D3 receptor antagonist compounds
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
SG11202001340VA (en) Quinoxaline derivatives as adenosine receptor antagonists
IL253848A0 (en) Amine compounds as 5-hydroxytryptamine 4 receptor agonists
GB201702617D0 (en) Receptor
PL3661941T3 (pl) Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego
IL271694A (en) Novel uses of a pure 6HT–5 receptor antagonist
HK1258023A1 (zh) 純5-ht6受體拮抗劑與nmda受體拮抗劑的組合
EP3350167A4 (en) Androgen receptor Antagonist
SG11202001337XA (en) Bezimidazole derivatives as adenosine receptor antagonists
EP3865472C0 (en) THROMBOXAN RECEPTOR ANTAGONISTS
ZA202000758B (en) Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
HK1231414A1 (zh) 胃輕癱用 受體激動劑
EP3388423A4 (en) NK1 RECEPTOR ANTAGONIST
GB201805675D0 (en) Compounds For Use As Apelin Receptor Antagonists
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
GB201513871D0 (en) Bicyclo dopamine D3 receptor antagonists
GB201419433D0 (en) Dopamine D3 receptor antagonist compounds
GB201419430D0 (en) Dopamine D3 receptor antagonist compounds